Plus   Neg

Eli Lilly & Co. (LLY) Surged To A New High On Alzheimer's Study Results

Eli Lilly & Co. (LLY) announced results from its Phase 3 EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease Monday afternoon. The results showed that patients with mild Alzheimer's disease taking solanezumab demonstrated a slowing of cognitive decline compared with placebo.

Eli Lilly & Co. climbed steadily following the release of the study results and finished up by 2.55 at $50.78 on strong volume. The stock has been rising for the past week and surged to a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT